North America Liver Disease Diagnostics Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends
Top Countries — Revenue
Access the full forecast model.
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
North America Liver Disease Diagnostics Market Analysis — Presence
Geographical Analysis
Click countries to exploreCountry Analysis
North America Liver Disease Diagnostics Market Analysis 2026
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|---|---|---|---|
| North America Liver Disease Diagnostics Total | xxxx | xxxx | xxxx | 6.2% |
| United States | xxxx | xxxx | xxxx | 6% |
| Canada | xxxx | xxxx | xxxx | 7% |
| Mexico | xxxx | xxxx | xxxx | 6.7% |
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Segmentation Analysis
Disease Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Liver Disease Diagnostics Market
The competitive context of the liver disease diagnostics industry offers information broken down by competition. In-depth information is provided about the business's background, finances, earnings, prospective markets, R&D spending, emerging market efforts, international manufacturing locations and infrastructure, manufacturing capabilities, company advantages and disadvantages, introduction of products, goods length and dimension, and sector superiority. The earlier statistics only pertain to the companies' concentration on the liver disease diagnostics industry.
April 2024: Roche declared that the Phase III STARGLO trial achieved its main objective, which was long-term survival. A longer life span was observed in patients with returned or resistant (R/R) lymphoma of the large B cells (DLBCL) that had already undergone one round of treatment and were not eligible for an autologous stem cell transplant when given the combination of Columvi (glofitamab) using the drugs gemcitabine and treatment with (GemOx) instead of MabThera/Rituxan (rituximab) with GemOx. (Source: https://www.roche.com/media/releases/med-cor-2024-04-15) July 2024: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), declared the release of a review article titled "Designed Recoverable Prevention of SpyCatcher Interaction Allows Quick Development of Bispecific Antibodies" in Environment Communications. This study shows how Bio-Rad's SpyLock technique can be used to quickly generate and evaluate bispecific antigens, which considerably speeds up the functionality confirmation procedure and helps identify those with the greatest potential. (Source: https://www.bio-rad.com/en-in/life-science-research/news/bio-rads-study-demonstrating-utility-its-spylock-technology-for-fast-generation-screening-bispecific-antibodies-published-nature-communications?ID=Bio-Rad-Publishes-in_1721753523) June 2024: Prisma Health and Siemens Healthineers established a ten-year collaboration to improve South Carolina's healthcare. The goals of this strategic collaboration are to improve medical care for Prisma Wellness's beneficiaries and the communities it serves, as well as to innovate treatment while training the staff. Siemens Healthineers and Prisma Health will work together to enhance the execution of health services, establish an Artificial Analytics Center with the aim of improving medical services, and install the newest healthcare equipment at all Prisma Health locations through this partnership. (Source: https://www.siemens-healthineers.com/press/releases/prisma)
| Top Companies (In no particular order) | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Company 1 | ••• | ••• | ••• | ••• |
| Company 2 | ••• | ••• | ••• | ••• |
| Company 3 | ••• | ••• | ••• | ••• |
| Company 4 | ••• | ••• | ••• | ••• |
| Company 5 | ••• | ••• | ••• | ••• |
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
Request company profile for validation →Report Scope & Analysis
According to Cognitive Market Research, the global liver disease diagnostics market size was estimated at USD 41548.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 16619.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
- According to Cognitive Market Research, the US had a major share in the liver disease diagnostics market with a market size of USD 13112.61 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The nation's increasing investment in infrastructure.
- The Canada liver disease diagnostics market had a market share of USD 1994.31 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Canada's rise is due to the nation's rapid expansion in the healthcare industry.
- The Mexico liver disease diagnostics market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 1512.35 million in 2024.
North America's liver disease diagnostics market is thriving because liver illness is becoming more common, new detection and therapy modalities are being adopted progressively, and the amount of neglected demand is rising. Moreover, the market is driven by significant firms' greater attempts to create rapid, extremely accurate diagnostics to identify liver diseases in particular regions. In conclusion, the North American market is driven by the increasing prevalence of diseases.
Analyst Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The North America Liver Disease Diagnostics Market Analysis is witnessing significant growth in the near future.
In 2023, the Hepatitis segment accounted for a notable share of the North America Liver Disease Diagnostics Market Analysis.
Driven by a passion for transforming complex digital and business data into actionable market intelligence, Aarti Bagekari focuses her research expertise on the Services & Software and Internet & Communication sectors. Her professional interests lie in analyzing evolving technology ecosystems, digital business models, software innovation, communication infrastructure, and emerging trends that are reshaping the global digital economy.
By leveraging a combination of primary and secondary research methodologies, Aarti develops comprehensive market perspectives that enable organizations to make informed strategic decisions in highly dynamic and competitive environments. Her work involves engaging with industry experts, technology providers, service operators, and key stakeholders while conducting extensive analysis of market data, industry developments, regulatory landscapes, and competitive dynamics. This balanced research approach allows her to uncover meaningful market patterns and identify opportunities that support long-term business growth.
Aarti possesses strong capabilities in market sizing and forecasting, competitive benchmarking, customer and stakeholder research, technology trend analysis, and strategic market assessment. She regularly evaluates developments across software solutions, cloud computing, digital services, telecommunications, internet platforms, enterprise technologies, and next-generation communication networks. Her ability to synthesize large volumes of information into clear and actionable insights helps organizations better understand market shifts, customer expectations, and emerging business opportunities.
At Cognitive Market Research & Consulting, Aarti contributes to market research reports, custom consulting engagements, and survey-based studies that support technology vendors, service providers, investors, and enterprise decision-makers. Her analytical mindset, attention to detail, and commitment to research excellence enable clients to navigate rapidly evolving digital markets, strengthen competitive positioning, and develop sustainable growth strategies in an increasingly connected world.
Frequently Asked Questions
★ Reviews
Rate this report
North America Liver Disease Diagnostics Market Analysis — Table of Contents
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
| Disease Type | Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD) |
|---|---|
| Diagnosis Technique | Imaging, Laboratory tests, Endoscopy, Biopsy, Others |
| End-use | Hospitals, Laboratories, Others |
| List of Competitors | Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd., F. Hoffmann-La Roche Ltd., HORIBA Medical, Laboratory Corporation of America Holdings, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc |
Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))
- 1.1 Top Competitors Analysis
- 1.1.1 Top Players Ranking 2024
- 1.1.2 New Product Launch Analysis
- 1.2 Company Profile (Data Subject to Availability) Sample Format
- 1.2.1 Abbott Laboratories
- 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.1.2 Business Overview
- 1.2.1.3 R&D Investment (Subject to data availability)
- 1.2.1.4 Financials (Subject to data availability)
- 1.2.1.5 Product Types Specification
- 1.2.1.6 Business Strategy
- 1.2.1.7 Recent Developments
- 1.2.1.8 Management Change
- 1.2.1.9 S.W.O.T Analysis
- 1.2.2 BioMerieux SA
- 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.2.2 Business Overview
- 1.2.2.3 R&D Investment (Subject to data availability)
- 1.2.2.4 Financials (Subject to data availability)
- 1.2.2.5 Product Types Specification
- 1.2.2.6 Business Strategy
- 1.2.2.7 Recent Developments
- 1.2.2.8 Management Change
- 1.2.2.9 S.W.O.T Analysis
- 1.2.3 Bio-Rad Laboratories Inc.
- 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.3.2 Business Overview
- 1.2.3.3 R&D Investment (Subject to data availability)
- 1.2.3.4 Financials (Subject to data availability)
- 1.2.3.5 Product Types Specification
- 1.2.3.6 Business Strategy
- 1.2.3.7 Recent Developments
- 1.2.3.8 Management Change
- 1.2.3.9 S.W.O.T Analysis
- 1.2.4 Cosara Diagnostics Pvt Ltd.
- 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.4.2 Business Overview
- 1.2.4.3 R&D Investment (Subject to data availability)
- 1.2.4.4 Financials (Subject to data availability)
- 1.2.4.5 Product Types Specification
- 1.2.4.6 Business Strategy
- 1.2.4.7 Recent Developments
- 1.2.4.8 Management Change
- 1.2.4.9 S.W.O.T Analysis
- 1.2.5 F. Hoffmann-La Roche Ltd.
- 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.5.2 Business Overview
- 1.2.5.3 R&D Investment (Subject to data availability)
- 1.2.5.4 Financials (Subject to data availability)
- 1.2.5.5 Product Types Specification
- 1.2.5.6 Business Strategy
- 1.2.5.7 Recent Developments
- 1.2.5.8 Management Change
- 1.2.5.9 S.W.O.T Analysis
- 1.2.6 HORIBA Medical
- 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.6.2 Business Overview
- 1.2.6.3 R&D Investment (Subject to data availability)
- 1.2.6.4 Financials (Subject to data availability)
- 1.2.6.5 Product Types Specification
- 1.2.6.6 Business Strategy
- 1.2.6.7 Recent Developments
- 1.2.6.8 Management Change
- 1.2.6.9 S.W.O.T Analysis
- 1.2.7 Laboratory Corporation of America Holdings
- 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.7.2 Business Overview
- 1.2.7.3 R&D Investment (Subject to data availability)
- 1.2.7.4 Financials (Subject to data availability)
- 1.2.7.5 Product Types Specification
- 1.2.7.6 Business Strategy
- 1.2.7.7 Recent Developments
- 1.2.7.8 Management Change
- 1.2.7.9 S.W.O.T Analysis
- 1.2.8 Meril Life Sciences Pvt. Ltd.
- 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.8.2 Business Overview
- 1.2.8.3 R&D Investment (Subject to data availability)
- 1.2.8.4 Financials (Subject to data availability)
- 1.2.8.5 Product Types Specification
- 1.2.8.6 Business Strategy
- 1.2.8.7 Recent Developments
- 1.2.8.8 Management Change
- 1.2.8.9 S.W.O.T Analysis
- 1.2.9 Qiagen N.V.
- 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.9.2 Business Overview
- 1.2.9.3 R&D Investment (Subject to data availability)
- 1.2.9.4 Financials (Subject to data availability)
- 1.2.9.5 Product Types Specification
- 1.2.9.6 Business Strategy
- 1.2.9.7 Recent Developments
- 1.2.9.8 Management Change
- 1.2.9.9 S.W.O.T Analysis
- 1.2.10 Siemens Healthcare GmbH
- 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.10.2 Business Overview
- 1.2.10.3 R&D Investment (Subject to data availability)
- 1.2.10.4 Financials (Subject to data availability)
- 1.2.10.5 Product Types Specification
- 1.2.10.6 Business Strategy
- 1.2.10.7 Recent Developments
- 1.2.10.8 Management Change
- 1.2.10.9 S.W.O.T Analysis
- 1.2.11 Thermo Fisher Scientific Inc
- 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
- 1.2.11.2 Business Overview
- 1.2.11.3 R&D Investment (Subject to data availability)
- 1.2.11.4 Financials (Subject to data availability)
- 1.2.11.5 Product Types Specification
- 1.2.11.6 Business Strategy
- 1.2.11.7 Recent Developments
- 1.2.11.8 Management Change
- 1.2.11.9 S.W.O.T Analysis
- 1.2.1 Abbott Laboratories
- 1.1 Top Competitors Analysis
Chapter 2. Global Liver Disease Diagnostics Market Analysis
- 2.1 Global Liver Disease Diagnostics Market Analysis
- 2.2 Global Liver Disease Diagnostics Market Analysis by Disease Type
- 2.3 Global Liver Disease Diagnostics Market Analysis by Diagnosis Technique
- 2.4 Global Liver Disease Diagnostics Market Analysis by End-use
Chapter 3. North America Liver Disease Diagnostics Market Analysis
- 3.1 North America Liver Disease Diagnostics Market Analysis
- 3.2 North America Liver Disease Diagnostics Market Analysis by Country
- 3.3 North America Liver Disease Diagnostics Market Analysis by Disease Type
- 3.4 North America Liver Disease Diagnostics Market Analysis by Diagnosis Technique
- 3.5 North America Liver Disease Diagnostics Market Analysis by End-use
- 3.6 North America Liver Disease Diagnostics Market Analysis by Key Players
Chapter 4. United States Liver Disease Diagnostics Market Analysis
- 4.1 United States Liver Disease Diagnostics Market Analysis
- 4.2 United States Liver Disease Diagnostics Market Analysis by Disease Type
- 4.3 United States Liver Disease Diagnostics Market Analysis by Diagnosis Technique
- 4.4 United States Liver Disease Diagnostics Market Analysis by End-use
- 4.5 United States Liver Disease Diagnostics Market Analysis by Key Players
Chapter 5. Canada Liver Disease Diagnostics Market Analysis
- 5.1 Canada Liver Disease Diagnostics Market Analysis
- 5.2 Canada Liver Disease Diagnostics Market Analysis by Disease Type
- 5.3 Canada Liver Disease Diagnostics Market Analysis by Diagnosis Technique
- 5.4 Canada Liver Disease Diagnostics Market Analysis by End-use
- 5.5 Canada Liver Disease Diagnostics Market Analysis by Key Players
Chapter 6. Mexico Liver Disease Diagnostics Market Analysis
- 6.1 Mexico Liver Disease Diagnostics Market Analysis
- 6.2 Mexico Liver Disease Diagnostics Market Analysis by Disease Type
- 6.3 Mexico Liver Disease Diagnostics Market Analysis by Diagnosis Technique
- 6.4 Mexico Liver Disease Diagnostics Market Analysis by End-use
- 6.5 Mexico Liver Disease Diagnostics Market Analysis by Key Players
Chapter 7. Disease Type Analysis
- 7.1 Hepatitis
- 7.2 Cirrhosis
- 7.3 Liver Cancer
- 7.4 Non-Alcoholic Fatty Liver Disease (NAFLD)
Chapter 8. Diagnosis Technique Analysis
- 8.1 Imaging
- 8.2 Laboratory tests
- 8.3 Endoscopy
- 8.4 Biopsy
- 8.5 Others
Chapter 9. End-use Analysis
- 9.1 Hospitals
- 9.2 Laboratories
- 9.3 Others
Chapter 10. Qualitative Analysis (Subject to Data Availability)
- 10.1 Market Drivers
- 10.2 Market Restraints
- 10.3 Market Trends
- 10.4 Market Opportunity
- 10.5 Technological Road Map (Subject to Data Availability)
- 10.6 Product Life Cycle (Subject to Data Availability)
- 10.7 Customer and Buyer Behavior Analysis
- 10.7.1 Digital Engagement, Customer Experience & Relationship Analysis
- 10.7.2 Customer Buying Behavior & Purchase Decision Analysis
- 10.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
- 10.7.4 Pricing, Affordability & Value Perception Analysis
- 10.7.5 Customer Segmentation & Demand Pattern Analysis
- 10.8 Industrial Chain Analysis (Subject to Data Availability)
- 10.8.1 Industry Chain Analysis
- 10.8.2 Manufacturing Cost Analysis
- 10.8.3 Supply Side Analysis
- 10.8.3.1 Raw Material Analysis
- 10.8.3.2 Raw Material Procurement Analysis
- 10.8.3.3 Raw Material Price Trend Analysis
- 10.9 PESTEL Analysis
- 10.9.1 Environmental Factors
- 10.9.2 Legal Factors
- 10.9.3 Technological Factors
- 10.9.4 Economic Factors
- 10.9.5 Political Factors
- 10.9.6 Social Factors
- 10.10 Porter’s Five Forces Analysis
- 10.10.1 Degree of Competition
- 10.10.2 Threat of Substitutes
- 10.10.3 Threat of New Entrants
- 10.10.4 Bargaining Power of Buyers
- 10.10.5 Bargaining Power of Suppliers
- 10.11 Patent Analysis (Subject to Data Availability)
- 10.12 ESG Analysis
- 10.13 Geopolitical Outlook
- 10.13.1 Global Power Realignment & Strategic Alliances
- 10.13.2 Geopolitical Risk Landscape & Conflict Hotspots
- 10.13.3 International Trade Relations & Market Access Environment
- 10.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
- 10.13.5 Supply Chain Resilience, Localization & Resource Nationalism
- 10.13.6 Technology Sovereignty & Digital Geopolitics
- 10.13.7 Strategic Implications for Investment, Growth & Market Entry
- 10.14 AI & Market Transformation
- 10.14.1 Competitive Landscape Disruption & Strategic Shifts
- 10.14.2 AI-Driven Transformation of Industry Value Chain
- 10.14.3 Evolution of Business Models & Revenue Streams
- 10.14.4 AI-Driven Product, Service & Innovation Transformation
- 10.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 11. Research Findings
- 11.1 Key Takeaways
- 11.2 Analyst Point of View
- 11.3 Assumptions and Acronyms
Chapter 12. Research Methodology and Sources
- 12.1 Primary Data Collection
- 12.1.1 Steps for Primary Data Collection
- 12.1.1.1 Identification of KOL
- 12.1.2 Backward Integration
- 12.1.3 Forward Integration
- 12.1.4 How Primary Research Help Us
- 12.1.5 Modes of Primary Research
- 12.1.1 Steps for Primary Data Collection
- 12.2 Secondary Research
- 12.2.1 How Secondary Research Help Us
- 12.2.2 Sources of Secondary Research
- 12.3 Data Validation
- 12.3.1 Data Triangulation
- 12.4 Data Representation
- 12.1 Primary Data Collection
Athenaeum AI Dashboard
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Aarti Bagekari and team for the North America Liver Disease Diagnostics Market Analysis Market analysis.
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
Data Assurance Metrics
Analytical Coverage
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Sources from the Service and Software Industry
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Liver Disease Diagnostics Market Analysis market.
Market Survey
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america liver disease diagnostics market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
- Buyer intent & sentiment analysis
- Purchase cycle mapping
- Price sensitivity research
- Channel preference profiling
- Competitive perception study
Customized Market Data & Reports
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
- Ready syndicate report
- Custom data scope & segmentation
- Excel quantitative models
- Board-ready PPT with key findings
- Secure cloud portal access
Strategic Consultation
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
- Dedicated analyst assigned to you
- Live walkthrough of findings
- Strategic Q&A sessions
- Go-to-market recommendations
- NDA-protected engagement
Customize This Report
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
